Are CWAN, SEM, GLDD Obtaining Fair Deals for their Shareholders?

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

Key Figures

SEM deal price: $16.50 per share CWAN deal price: $24.55 per share GLDD deal price: $17.00 per share

3 metrics

SEM deal price $16.50 per share Cash sale of Select Medical Holdings Corporation

CWAN deal price $24.55 per share Cash sale of Clearwater Analytics Holdings, Inc.

GLDD deal price $17.00 per share Cash sale of Great Lakes Dredge & Dock Corporation

Market Reality Check

Price: $16.25 Vol: Volume 1,572,716 is 0.74x...

normal vol

$16.25 Last Close

Volume Volume 1,572,716 is 0.74x the 20-day average of 2,111,191, suggesting limited reaction ahead of this legal-focused headline. normal

Technical At $16.25, SEM trades above its $14.29 200-day MA but about 12.66% below its $18.605 52-week high, and modestly below the announced deal price of $16.50.

Peers on Argus

SEM was unchanged while sector peers were mixed: PIII rose 29.08%, ARDT gained 4...

1 Up 1 Down

SEM was unchanged while sector peers were mixed: PIII rose 29.08%, ARDT gained 4.92%, AVAH added 2.24%, PACS inched up 0.29%, and NHC fell 2.35%. Momentum scanner flagged PIII up 32.52% and ASTH down 6.96%, with no news on those names, reinforcing that SEM’s flat trade and deal-focused legal headline appear stock-specific rather than part of a sector-wide move.

Historical Context

5 past events · Latest: Mar 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Deal fairness inquiry	Negative	+0.0%	Law firm questioned fairness of SEM’s proposed sale terms for shareholders.
Mar 02	Go-private agreement	Positive	+8.4%	Consortium agreed to acquire SEM for <b>$16.50</b> per share in cash.
Feb 19	Earnings & dividend	Positive	-6.7%	Reported 2025 growth, 2026 outlook, dividend and buyback plan.
Feb 17	Sponsorship extension	Positive	+0.0%	Extended NovaCare Rehabilitation’s role as Philadelphia Eagles’ therapy partner.
Feb 17	Earnings timing	Neutral	+0.0%	Announced schedule for Q4/FY2025 results and outlook conference call.

Pattern Detected

Recent SEM deal and fundamental news often saw price moves that diverged from the apparent tone, including a selloff on strong 2025 results and a flat reaction to legal deal-scrutiny items.

Recent Company History

Over the last few weeks, SEM has been shaped by a go-private process at $16.50 per share, an enterprise value of $3.9 billion, and robust 2025 results with detailed 2026 guidance. Earlier, the company announced earnings timing and renewed a long-standing NovaCare partnership with the Philadelphia Eagles. A prior March 6 shareholder-rights investigation headline similar to today’s saw no price reaction. Today’s law-firm inquiry fits into this ongoing debate over deal terms rather than introducing a new strategic direction.

Market Pulse Summary

This announcement highlights an investor-rights law firm reviewing whether SEM’s agreed cash sale at...

Analysis

This announcement highlights an investor-rights law firm reviewing whether SEM’s agreed cash sale at $16.50 per share provides fair value and adequate process for shareholders. In recent months, SEM has combined a go-private agreement with solid 2025 operating results and detailed 2026 guidance. Investors may watch for any court filings, supplemental disclosures, or changes in merger terms, alongside ongoing regulatory and shareholder approvals tied to the take-private transaction.

Key Terms

federal securities laws, fiduciary duties, contingent fee basis

3 terms

federal securities laws regulatory

"investigating the following companies for potential violations of the federal securities laws"

Federal securities laws are the set of national rules that require companies and market participants to provide accurate information, prohibit deceptive practices, and ensure fair trading of stocks and bonds. Think of them as the rules of the road for financial markets: they help investors make informed choices by mandating disclosures and punishing fraud, which reduces risk and builds trust in the safety and reliability of investments.

fiduciary duties regulatory

"and/or breaches of fiduciary duties to shareholders relating to"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

contingent fee basis financial

"We would handle any matter on a contingent fee basis, whereby you would not"

A contingent fee basis is an arrangement where payment is made only if a specified outcome is achieved, like a lawyer getting paid only when a lawsuit succeeds or a finder receiving a commission only if a deal closes. For investors, it matters because contingent obligations shift risk off the payer and onto the payee, can reduce upfront costs but create future liabilities or incentives that affect valuations and the alignment of interests — think of it as a “pay-if-success” bet on a specific result.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 10, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Clearwater Analytics Holdings, Inc. (NYSE: CWAN)'s sale to Permira and Warburg Pincus for $24.55 per share in cash. If you are a Clearwater shareholder, click here to learn more about your rights and options.

Select Medical Holdings Corporation (NYSE: SEM)'s sale to a consortium led by Select Medical executives and directors for $16.50 in cash per share. If you are a Select Medical shareholder, click here to learn more about your rights and options.

Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD)'s sale to Saltchuk Resources, Inc. for $17.00 per share in cash. If you are a Great Lakes shareholder, click here to learn more about your rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-cwan-sem-gldd-obtaining-fair-deals-for-their-shareholders-302709761.html

SOURCE Halper Sadeh LLP